Triple Combination Immunotherapy for Lung Cancer
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: Washington University School of Medicine
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial
Trial Summary
What is the purpose of this trial?
This trial is testing a combination of three drugs to help the immune system fight lung cancer. The drugs are zimberelimab, domvanalimab, and etrumadenant. They are being tested on patients who have already tried other immune-based treatments. The goal is to see if this new combination can work better.
Research Team
Daniel Morgensztern
Principal Investigator
Washington University School of Medicine
Eligibility Criteria
This trial is for adults with non-small cell lung cancer who've had previous treatments including immune checkpoint blockers. They must have at least one measurable tumor and cannot have more than two prior therapies in the metastatic setting. Participants need normal organ function, no severe psychiatric issues or substance abuse, not be pregnant/breastfeeding, and can't have certain other cancers or active autoimmune diseases.Inclusion Criteria
We don't know how the study drugs might affect a developing baby in the womb.
My bone marrow and organs are functioning normally.
My cancer shows PD-L1 expression of 1% or more.
See 7 more
Exclusion Criteria
Pregnant and/or breastfeeding
I have not received any live vaccines in the last 28 days.
You have had allergic reactions to similar drugs as zimberelimab, domvanalimab, etrumadenant, or other drugs used in the study.
See 9 more
Treatment Details
Interventions
- Domvanalimab
- Etrumadenant
- Zimberelimab
Trial OverviewThe study tests a combination of three drugs: Zimberelimab, Domvanalimab, and Etrumadenant on patients with non-small cell lung cancer who didn't respond well to previous treatments. It explores how these drugs work together since they target different aspects of the immune system's ability to fight cancer.
Participant Groups
2Treatment groups
Experimental Treatment
Group I: Cohort B: Zimberelimab + Domvanalimab + EtrumadenantExperimental Treatment3 Interventions
* Patients will be treated on 21-day cycles with 360 mg zimberelimab intravenously on Day 1, 15 mg/kg domvanalimab intravenously on Day 1, and 150 mg etrumadenant orally daily on Days 1 to 21.
* Cohort B participants are those that have PD-L1 ≥ 50%.
Group II: Cohort A: Zimberelimab + Domvanalimab + EtrumadenantExperimental Treatment3 Interventions
* Patients will be treated on 21-day cycles with 360 mg zimberelimab intravenously on Day 1, 15 mg/kg domvanalimab intravenously on Day 1, and 150 mg etrumadenant orally daily on Days 1 to 21.
* Cohort A participants are those that have PD-L1 1-49%
Find a Clinic Near You
Who Is Running the Clinical Trial?
Washington University School of Medicine
Lead Sponsor
Trials
2,027
Recruited
2,353,000+
Arcus Biosciences, Inc.
Industry Sponsor
Trials
44
Recruited
7,500+
Other People Viewed
By Subject
By Trial
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.